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RepoRt
Antigens in the SC blood group system are expressed by the 
human erythrocyte membrane-associated protein (ERMAP). 
Two molecular bases have been reported for the Scnull phenotype: 
SC*307del2 and SC*994C>T. We report our investigation of the 
molecular background of five Scnull individuals from the Pacific 
Islands and describe the successful transfusion of Sc3+ blood 
to a patient with anti-Sc3 in her plasma. SC (ERMAP) exons 2, 
3, and 12 and their flanking intronic regions were analyzed. The 
SC*994C>T change introduces a restriction enzyme cleavage 
site for Tsp45I, and polymerase chain reaction (PCR) products 
from exon 12 were subjected to this PCR–restriction fragment 
length polymorphism (RFLP) assay. The five samples had the 
variant SC*994T/T. One sample, from a first cousin of one 
Marshallese proband, was heterozygous for SC*1514C/T (in the 
3′ untranslated region); the other four samples were SC*1514C/C 
(consensus sequence). Samples from white donors (n = 100) and 
African American donors (n = 99) were tested using the Tsp45I 
PCR-RFLP assay; all gave a banding pattern that was consistent 
with the SC*994C/C consensus sequence. In all five samples, 
our analyses showed homozygosity for the nonsense nucleotide 
change SC*994C>T in an allele carrying the nucleotide associated 
with Sc1. Further investigation determined that one of the 
probands reported previously with the SC*994C>T change was 
from the Marshall Islands (which form part of the Micronesian 
Pacific Islands) and the other was from an unspecified location 
within the large collection of Pacific Islands. Taken together, the 
five known probands with the SC*994C>T silencing nucleotide 
change were from the Pacific Islands. Immunohematology 
2013;29:69–72.
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The Scianna (SC) blood group system (ISBT 013) consists 
of seven antigens: Sc1 (SC1), Sc2 (SC2), Sc3 (SC3), Rd (SC4), 
STAR (SC5), SCER (SC6), and SCAN (SC7). Sc1, a high-
prevalence antigen, and Sc2, a low-prevalence antigen, are 
antithetical; Sc3, STAR, SCER, SCAN are high-prevalence 
antigens, and Rd is a low-prevalence antigen. These antigens 
are expressed by the human erythrocyte membrane-associated 
protein (ERMAP), which is a member of the immunoglobulin 
superfamily.1 The gene encoding this membrane protein, 
ERMAP, is located on chromosome 1p34.2, close to RHD and 
RHCE.2,3
The SC:–1,–2,–3 type represents the Scnull phenotype, 
and people with this phenotype are apparently healthy. Two 
molecular bases for this phenotype have been reported: a 
deletion of two nucleotides in exon 3 of SC (SC*307del2; ISBT 
provisional allele name SC*01N.01) in a Saudi Arabian, and 
a nucleotide change in exon 11 (now known to be exon 12) 
of SC (944C>T, Arg332Stop; ISBT provisional allele name 
SC*01N.02) in two probands, one with a concomitant 1514C>T 
change in the 3′-untranslated region of SC.1 The ethnicity for 
the latter two patients was not stated in that paper (3rd and 4th 
entries in Table 1).4 Since publication of the Flegel et al paper 
in 2005,4 it has been shown that ERMAP consists of 12, not 
11, exons (reviewed by Brunker and Flegel5). Based on this 
knowledge, we believe the SC*944C>T nucleotide change occurs 
in exon 12. The reference sequence for the 12-exon ERMAP 
(SC) model in the human genome can be found at http://
www.ncbi.nlm.nih.gov/gene/114625, and in the RefSeqGene 
it is found at NM_001017922.1. When we began the study 
described here, we used transcript NM_018538.3, which has 
11 exons; fortunately, as the additional exon is upstream from 
the initiation sequence in both transcripts, the sequence for 
blood group antigen expression, whether the previous exon 
11 or updated exon 12 is used, is the same. Throughout this 
manuscript, we use the 12-exon transcript model.
We report the molecular background of the Scnull 
phenotype in five individuals (three probands who were 
found because they had anti-Sc3 in their plasma) and for the 
first time report that the SC*994C>T nucleotide change is 
associated with Pacific Islanders. We also describe a case in 
which crossmatch-incompatible Sc3+ blood was successfully 
transfused to a patient with anti-Sc3 in her plasma.
Case Report
Case 1
Case 1 was a 24-year-old from the Marshall Islands with 
metastatic ovarian cancer. Despite considerable effort, we were 
unable to obtain a history regarding transfusion or pregnancy. 
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During routine testing her plasma was shown to contain an 
alloantibody to a high-prevalence antigen, strongly reactive 
in the indirect antiglobulin test (IAT), which was identified 
as anti-Sc3. Her red blood cells (RBCs) typed RH:1,2,–3,–4,5 
(R1R1); SC:–1,–2,–3, and typings for antigens in other blood 
group systems were unremarkable (and are not provided to 
protect the identity of the proband). Samples from two of her 
relatives (a first cousin and one for whom we could not obtain 
the relationship) were also tested.
Case 2
Case 2 was a 28-year-old from the Pacific Islands (despite 
considerable effort, a more specific location could not be 
ascertained), who was identified during her third pregnancy. 
She had no history of having been transfused, and there 
was no information about her prior pregnancies. Her plasma 
contained an alloantibody to a high-prevalence antigen, 
strongly reactive in the IAT, which was identified as anti-Sc3. 
Her RBCs typed RH:1,2,3,4,5 (R1R2); SC:–1,–2,–3; typings 
for antigens in other blood group systems were unremarkable 
(and are not provided to protect the identity of the proband).
Case 3
Case 3 was a 51-year-old Marshallese female who had a 
diagnosis of type 2 diabetes mellitus and anemia secondary 
to chronic disease, renal failure, and recurrent urosepsis. 
The patient had received two leukocyte-reduced components 
approximately 3 months before being admitted to the hospital 
and had a history of three pregnancies, which required cesarean 
delivery. She was admitted to the hospital with fever and 
nausea, a hemoglobin level of 7.2 g/dL, and a hematocrit of 20.9 
percent. Her plasma agglutinated all RBC samples in the IAT 
(titer 16, score 49) except her own. Her RBCs typed RH:1,2,–
3,–4,5 (R1R1); SC:–1,–2,–3, and her antibody was identified as 
anti-Sc3. Her RBCs were unremarkable for antigens in other 
blood group systems (and test results are not provided to protect 
the identity of the proband). Her hemoglobin dropped to 5.5 
g/dL and she required transfusion. As no SC:–1,–2,–3 blood 
was available for transfusion, she was transfused with three 
units of phenotype-matched but crossmatch-incompatible 
leukocyte-reduced packed RBCs. The patient appeared to 
tolerate the transfusion well, and her hemoglobin increased to 
11.1 g/dL, and her hematocrit, to 33.1 percent. On the fifth day 
after transfusion, she was discharged from the hospital with a 
hemoglobin of 10.2 g/dL and a hematocrit of 30.7 percent.
Materials and Methods
Samples and Hemagglutination Testing
Peripheral blood samples were freshly collected or 
recovered from liquid nitrogen storage after the institutional 
review board approved the protocol. Antigen testing, antibody 
detection, and antibody identification were performed in tubes 
using various enhancement media.6 RBC antigen typing for the 
Sc antigens was performed with in-house, unlicensed, single-
donor-source polyclonal antibodies from our collections.
Polymerase Chain Reaction Sequence Analysis of 
Genomic DNA
Genomic DNA was isolated from whole blood (QIAamp 
DNA Blood Mini Kit, QIAGEN, Inc., Valencia, CA) from 
the three probands and from the two relatives of one of the 
Marshallese (Case 1). The regions of SC that included and 
flanked exons 2, 3, and 12 were amplified separately using the 
oligonucleotide primers listed in Table 1. The primers were 
synthesized (Life Technologies, Inc., Gaithersburg, MD). Five 
microliters of DNA per reaction was amplified by 5 U of Taq DNA 
polymerase (HotStarTaq, QIAGEN) in a 50-μL reaction mix-
ture containing 1.5 mM MgCl2 for exon 2 and 2.0 mM MgCl2 
for exons 3 and 12, 1× polymerase chain reaction (PCR) buffer, 
0.2 mM deoxyribonucleoside 
triphosphates, and 100 ng of 
forward and reverse primers. 
Amplification was achieved over 
35 cycles with a final extension 
time of 10 minutes. The PCR 
products were then treated 
(ExoSAP-IT, USB, Cleveland, 
OH) before sequencing (Sanger 
dideoxy sequencing, GENEWIZ, 
South Plainfield, NJ). The PCR 
products were sequenced in both 
directions.
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Table 1. Oligonucleotide primers used in the analysis of individual exons of SC
Name Primer sequence (5′ to 3′)
Annealing 
temperature Exon (expected size [bp])
SCInt1F cctttgtgatcccagagcacc 62°C Exon 2 (309)
SCInt2R gggaacagaaccccaaaagaca
SCInt2F cttcctgggctctgtccgtc 60°C Exon 3 (557)
SCInt3R tacactgcagatgaaagaaaagtc
SCInt10F ggctaatgacagtgatggcag 60°C Exon 12 (948) for analysis of nucleotide 994
SCEx11R CCACAAAAGGGTCTGGATTTGG
SCEx11F CACAGCACCTCTAGTCATTTG 60°C Exon 12 (398) for analysis of nucleotide 1514
SC3UTR CCTTAGAAGAAAGGTAAGCTTC
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PCR–Restriction Fragment Length Polymorphism 
Analysis
Analysis of the nucleotide sequence of the variant revealed 
that the SC*994C>T nucleotide change induced a Tsp45I 
restriction enzyme cutting site, so the variant (SC*994T) could 
be distinguished from the consensus sequence (SC*994C) by 
a PCR–restriction fragment length polymorphism (RFLP) 
assay. PCR amplicons of 948 bp for exon 12 (see Table 1) were 
digested (Tsp45I restriction enzyme, New England Bio Labs, 
Ipswich, MA) and run on 8 percent polyacrylamide gels in a 
1× Tris-borate-EDTA buffer, at a voltage of 200 V for 2 hours. 
The expected sizes for the consensus sequence and variant are 
listed in Figure 1. Samples from African Americans (n = 99) 




RBCs from each proband and the two Scnull family 
members typed SC:–1,–2,–3. Plasma of the three probands 
contained anti-Sc3, each reacting 3+ in the IAT, and were 
mutually compatible. The plasma of the compatible (Scnull) 
first cousin of the Case 1 proband had no detectable irregular 
antibody. Plasma from the other relative of Case 1 was not 
available for testing.
Sequence Analysis of Genomic DNA and PCR-RFLP 
Assay
Sequence analyses of the three probands and the two 
relatives demonstrated consensus sequence for exons 2 and 
3, which is predicted to encode the SC:1,–2 phenotype and 
eliminated the published 307del2 (provisional ISBT allele 
name SC*01N.01) as a cause of the Scnull phenotype in these 
people. However, all five samples were homozygous for the 
SC*994C>T change (provisional ISBT allele name SC*01N.02; 
GenBank accession number JF828030) in exon 12, which is 
predicted to encode Arg332Stop, and revealed the cause of 
their Scnull phenotype. The SC*994C>T change in exon 12 was 
confirmed using the Tsp45I restriction enzyme assay. Four 
samples were homozygous for SC*1514C/C (consensus), and 
one sample, the first cousin of Case 1, was heterozygous for 
SC*1514C/T. For a summary of these findings, see Table 2.
RFLP analyses of the PCR products using genomic DNA 
from the five samples confirmed the homozygous SC*994C>T 
change (Fig. 1). A cohort of samples from two unrelated 
ethnic groups, 100 random whites and 99 random African 
Americans, were screened using this assay; all demonstrated 
the expected digestion pattern for the consensus SC*994C/C.
Discussion
We describe three Scnull probands (five individuals in total) 
from the Pacific Islands who have a homozygous nonsense 
nucleotide change of SC*994C>T in exon 12 in an allele 
carrying the nucleotide associated with the Sc1 antigen. In the 
publication of Flegel and colleagues,4 two Scnull probands with 
the SC*994C>T change were reported to be living in California. 
Since that original description (in 2005), we were able to 
obtain the ethnicity of these probands: the one with SC*994T, 
1514T was from an unspecified location within the large 
collection of Pacific Islands, and the one with SC*994T, 1514C 
was from a more precisely determined location, the Republic 
Fig. 1 Polymerase chain reaction–restriction fragment length 
polymorphism using Tsp45I for SC*994C>T. Analysis of PCR exon 
12 amplicons after digestion with Tsp45I in 8 percent polyacrylamide 
gel. Lane 1: 100-bp ladder. Lane 2: uncut PCR amplicon of 948 
bp. Lane 3 (Case 1), 4 (Case 2), and 5 (Case 3): digested PCR 
amplicon, which shows homozygosity for the variant SC*994T with 
bands of 432, 275, 127, and 114 bp. Lane 6: digested PCR product 
from a control with the consensus sequence, which shows bands of 
432, 402, and 114 bp.
Table 2. Results of four relevant nucleotides obtained from 
sequencing exons 2, 3, and 12 of SC






Case 1 G/G Consensus T/T C/C
First cousin of Case 1 G/G Consensus T/T C/T
Relative of Case 1 G/G Consensus T/T C/C
Case 2 G/G Consensus T/T C/C
Case 3 G/G Consensus T/T C/C
UTR = untranslated region.
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of the Marshall Islands. Taking the cases together, of the five 
probands described with the SC*994C>T silencing nucleotide 
change, two were from an unspecified location within the 
Pacific Islands and three were definitely Marshallese. This 
provides strong evidence for an association between SC*994T 
and the Marshallese or Pacific Islander populations.
We found further evidence for an association between 
Pacific Islanders and Scnull in two of three reports. The first 
reported Scnull phenotype was in 1973 (then Sm– Bu(a–), 
now SC:–1,–2 or Sc1–Sc2–) in a proband from a Marshallese 
pedigree.7 The second Scnull proband was reported to be a 
Caucasian male.8 The third reported proband was a Melanesian 
girl from Papua New Guinea; her mother was also SC:–1,–2. 
In testing 29 additional samples, six more Scnull were found; 
four were among family members and two were unrelated 
villagers.9 To our knowledge, DNA-based testing was not 
performed on these cases.
Although four individuals reported in this manuscript 
were SC*1514C/C (consensus), the first cousin of the Case 1 
proband was heterozygous SC*1514C/T in the 3′ untranslated 
region of exon 12 (rs111730740). This change in two probands 
(one in this report [heterozygote] and one in the original report 
[homozygote]4) shows there are two alleles with SC*994T, 
and it remains to be determined which is the founder allele. 
Interestingly, in the Single Nucleotide Polymorphism Database, 
the SC*1514C>T variant has been found in the heterozygous 
state (with the consensus SC*944C) in an individual from the 
Bushman population.
In the South Pacific, there are three cultural areas, namely 
Melanesia, Micronesia (which includes the Marshall Islands), 
and Polynesia. People from each of these three areas can be 
referred to as “Pacific Islanders.” In terms of blood groups, 
it is well known that Polynesians, who are Pacific Islanders, 
harbor the rare JK:–1,–2,–3 phenotype.10 In this paper, we 
reveal that a second rare null phenotype (SC:–1,–2,–3) is 
also found among Pacific Islanders. Thus, during the course 
of an antibody investigation in which an antibody to a high-
prevalence antigen is suspected in an individual from the 
geographic area in the South Pacific, consider the possibility of 
either anti-Jk3 or anti-Sc3.
Anti-Sc3 has been reported to cause no or mild delayed 
transfusion reactions and mild hemolytic disease of the 
fetus and newborn.11,12 Case 3 in this paper documents an 
additional case in which the anti-Sc3 was apparently clinically 
insignificant in transfusion.
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